Quarterly ResultMay 7, 2026, 08:18 AM
Delcath Systems Q1 Revenue $25.0M; Guides 2026 to $100M+
AI Summary
Delcath Systems reported first-quarter 2026 financial results, with total revenue increasing to $25.0 million from $19.8 million year-over-year, driven by strong HEPZATO KIT sales. Despite revenue growth, the company posted a net loss of $1.1 million compared to a net income in the prior year, and adjusted EBITDA declined. The company reaffirmed its full-year 2026 revenue guidance of at least $100 million and highlighted significant HEPZATO volume growth and positive clinical trial publication.
Key Highlights
- Total revenue for Q1 2026 increased to $25.0 million from $19.8 million in Q1 2025.
- HEPZATO KIT revenue grew to $23.3 million in Q1 2026 from $18.0 million in Q1 2025.
- Net loss for Q1 2026 was $1.1 million, compared to a net income of $1.1 million in Q1 2025.
- Non-GAAP adjusted EBITDA decreased to $3.4 million in Q1 2026 from $7.6 million in Q1 2025.
- Cash and investments stood at $89.3 million as of March 31, 2026, with no debt.
- Repurchased 316,023 common shares for approximately $3.0 million in Q1 2026.
- HEPZATO volume grew approximately 36% in Q1 2026 compared to Q1 2025.
- Issued 2026 revenue guidance of at least $100 million, with HEPZATO KIT volume growth of at least 20%.